Penumbra is a leading interventional technology company that develops and markets innovative medical devices to the neurovascular and peripheral vascular communities around the world.

InspireMD has aggressively been pursuing a strategy in treating carotid artery disease and other neurovascular applications for its proprietary MicroNet technology.

Clinical trials of the CGuard system, including the recent CARENET and PARADIGM studies, have continued to support the benefits of the MicroNet enhanced CGuard system resulting in increased commercial adoption throughout the European market.

Penumbra has a direct and distributor sales organization in all markets where the CGuard system is commercially available.

Penumbra’s neurovascular product portfolio includes medical devices for ischemic stroke and brain aneurysms, as well as peripheral vascular products that include products for embolization and thrombectomy.

Penumbra has approximately 1,000 global employees with direct sales operations in North America, Europe, and Australia. Penumbra sells through distributors in Asia and select other international markets.

Alan Milinazzo, CEO of InspireMD, commented, "We are excited to partner with a leading global organization such as Penumbra. The Penumbra commercial organization is a well-respected, strong and growing team of experienced professionals that will help communicate the benefits of our proprietary CGuard EPS to all specialists that manage carotid artery disease."

"In addition, Jim Pray, President, International of Penumbra, stated, "The Penumbra team is looking forward to offering the CGuard to our customers. The CGuard carotid system from InspireMD is unique and addresses many limitations of existing carotid stents.

The CGuard offers an unmatched ability to protect against plaque protrusion and prevent embolic events. The InspireMD team has done a remarkable job getting this breakthrough technology to market and our customers are looking forward to incorporating it into their practices. We are fortunate to be able to partner with InspireMD."

CGuard EPS is CE Mark approved. CGuard EPS, however, is not approved for sales in the U.S. by the U.S. Food and Drug Administration at this time.